Hub : Traits :

Forced expiratory volume in 1-second (FEV1), predicted

743 significantly associated models · 174 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 16273995 18074702 8 1 1.3e-12 8.8e-12 1.1e-01 94 MST1P9
2 1 40748755 42406344 2 1 5.5e-12 2.3e-11 7.3e-03 84 SCMH1
3 1 50735395 52135979 1 1 5.1e-09 9.1e-10 2.7e-02 87 CDKN2C
4 1 149672809 150515021 3 1 1.6e-09 6.2e-16 6.5e-08 55 RP11-196G18.22
5 1 183325796 184739300 1 1 5.1e-16 7.2e-16 6.8e-02 95 TSEN15
6 2 24348096 25837917 2 1 7.9e-09 2.1e-10 6.5e-06 50 ADCY3
7 2 55401562 56843605 1 1 9.3e-11 1.8e-13 2.3e-04 75 EFEMP1
8 2 168949234 170419444 2 1 1.2e-12 6.4e-11 1.6e-03 77 NOSTRIN
9 2 218827778 220226393 1 1 5.4e-08 5.1e-06 1.1e-01 87 BCS1L
10 2 231913056 233446568 3 2 2.6e-10 3.0e-08 7.0e-01 100 DIS3L2 PDE6D
11 3 49615624 50998816 1 1 9.3e-08 2.5e-07 6.8e-01 99 SEMA3B-AS1
12 3 56341514 56902096 1 1 2.0e-07 2.9e-06 5.2e-01 98 CCDC66
13 3 128788778 129284415 1 1 1.4e-07 1.3e-06 4.8e-02 83 H1FX
14 3 140350567 141867638 1 1 5.1e-30 6.1e-30 1.0e+00 100 ZBTB38
15 4 17104059 18507692 2 1 8.2e-27 6.6e-28 1.0e-05 84 DCAF16
16 4 145203531 146788825 2 2 9.4e-13 7.0e-23 4.8e-12 51 ANAPC10 OTUD4
17 5 130830617 132693330 8 1 5.3e-12 3.0e-09 1.0e+00 100 P4HA2
18 5 176040488 177260129 1 1 1.0e-12 3.4e-12 7.2e-03 85 RAB24
19 5 178968049 180374523 1 1 4.1e-08 8.4e-10 1.9e-03 74 MAPK9
20 6 7481928 8118906 1 1 3.3e-08 9.5e-13 4.0e-07 50 BMP6
21 6 33745071 36158878 9 7 3.2e-17 1.5e-19 NaN NaN C6orf106 RPL10A ZNF76
22 6 104478130 106230491 2 1 1.0e-10 1.2e-17 2.0e-08 57 LIN28B
23 6 125970401 127355237 1 1 8.9e-11 4.7e-12 1.6e-02 88 CENPW
24 6 129638583 131163098 2 1 2.4e-17 7.0e-16 1.0e+00 100 RP11-73O6.3
25 6 141924760 143855272 2 1 4.7e-17 1.8e-18 1.0e+00 100 GPR126
26 7 2032803 5003373 3 2 2.1e-15 2.5e-15 1.0e+00 100 GNA12 SDK1
27 7 23296533 23818538 1 1 1.2e-08 3.3e-09 1.2e-02 82 TRA2A
28 7 27623776 28468319 1 1 1.8e-10 2.1e-15 2.3e-06 64 JAZF1
29 7 91492103 93160671 2 1 4.2e-12 3.6e-14 8.4e-05 73 CDK6
30 8 130517157 131045893 1 1 3.8e-10 1.2e-10 7.7e-02 92 GSDMC
31 9 97573117 98969746 2 1 1.2e-09 1.2e-14 1.6e-11 24 RP11-435O5.5
32 9 138628816 140071683 2 1 4.0e-08 1.4e-07 8.1e-01 100 SEC16A
33 10 4334578 5844628 2 1 2.8e-09 7.2e-08 1.0e+00 100 AKR1C3
34 10 103527782 105275242 7 1 6.4e-11 2.7e-08 2.8e-01 96 TMEM180
35 11 66468469 67856510 1 1 2.3e-17 3.0e-17 1.0e+00 100 RAD9A
36 12 191619 1190134 1 1 1.8e-07 1.5e-07 9.6e-04 60 KDM5A
37 12 27587038 29432481 2 1 6.0e-13 1.4e-13 2.0e-02 90 CCDC91
38 12 55677395 57452308 7 1 1.9e-08 1.2e-07 9.8e-01 100 IL23A
39 13 49557805 51390447 2 2 2.2e-07 1.3e-12 2.8e-10 21 DLEU2 EBPL
40 14 91831899 93223990 1 1 1.1e-07 1.7e-07 1.0e+00 100 RP11-529H20.5
41 15 73524629 74915888 1 1 1.6e-07 2.6e-06 2.4e-04 39 LOXL1-AS1
42 15 84151637 85895721 11 1 7.6e-14 2.4e-15 1.0e-06 62 AC103965.1
43 15 89192873 89701439 1 1 2.1e-08 2.8e-12 2.1e-12 -1 MFGE8
44 15 99816860 101209341 1 1 1.5e-08 5.7e-10 7.1e-08 24 CTD-3076O17.1
45 16 1994980 2502641 2 1 4.1e-08 1.0e-06 2.8e-01 95 CASKIN1
46 16 89825065 90172696 1 1 9.4e-08 1.1e-05 1.8e-01 91 DBNDD1
47 17 6652789 8112253 3 1 3.4e-08 5.1e-08 1.8e-01 94 CHRNB1
48 17 17484654 18914778 1 1 1.9e-07 6.0e-07 6.3e-01 99 TOP3A
49 17 28398977 30034689 3 2 2.4e-11 4.2e-18 3.2e-06 71 CRLF3 RP11-848P1.7
50 17 59245274 59736794 1 1 5.6e-08 4.6e-09 2.5e-02 85 C17orf82
51 17 60916262 62694738 9 2 9.8e-13 9.8e-12 2.1e-01 97 DDX42 SCN4A
52 18 20082830 21806700 3 1 1.3e-10 2.2e-24 1.5e-16 34 RIOK3
53 18 45873080 47686517 1 1 1.0e-07 3.1e-07 8.7e-02 89 DYM
54 19 1916392 2466607 1 1 5.1e-08 3.1e-09 1.0e+00 100 DOT1L
55 19 19378671 19892796 2 1 6.3e-08 3.0e-06 6.7e-01 99 TSSK6
56 20 31382860 35512648 35 11 1.4e-27 3.7e-30 NaN NaN CEP250 E2F1 GDF5 GGT7 MMP24 TP53INP2 UQCC UQCC1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.6 3 1 2.2 0.00 1.0e+00 AC103965.1 TP53INP2 TSSK6
Bipolar Disorder or Schizophrenia 1.7 1 1 2.2 0.00 1.0e+00 AC103965.1
Depressed Affect (Nagel 2018) 1.3 1 0 0.0 0.00 1.0e+00 LOXL1-AS1
Intelligence (Savage-Jansen 2018) 1.4 5 1 2.2 0.99 2.0e-03 CENPW DCAF16 DDX42 DLEU2 RP11-435O5.5
Neuroticism (Nagel 2018) 1.6 4 2 4.4 -0.99 1.4e-02 CENPW LIN28B LOXL1-AS1 TP53INP2
Schizophrenia (2018) 1.4 2 1 2.2 0.00 1.0e+00 AC103965.1 LIN28B
Worry (Nagel 2018) 1.6 3 0 0.0 0.00 1.0e+00 CENPW TMEM180 TP53INP2
Crohns Disease (2017) 2.0 4 3 6.7 0.79 2.1e-01 ADCY3 P4HA2 SEC16A ZBTB38
Irritable Bowel Disease (IBD) 1.8 4 2 4.4 0.65 3.5e-01 ADCY3 GNA12 P4HA2 SEC16A
Ulcerative Colitis (UC) 1.8 3 2 4.4 0.00 1.0e+00 GNA12 MMP24 SEC16A
Reaction Time 1.4 1 0 0.0 0.00 1.0e+00 TMEM180
Verbal and Numeric Reasoning (VNR) 1.5 2 1 2.2 0.00 1.0e+00 CENPW DCAF16
Breast Cancer 2.3 6 5 11.1 -0.54 2.7e-01 ADCY3 P4HA2 RP11-196G18.22 RP11-73O6.3 RP11-848P1.7 ZBTB38
Prostate Cancer 1.9 1 0 0.0 0.00 1.0e+00 TMEM180
Body Mass Index (BMI) (2010) 1.6 1 0 0.0 0.00 1.0e+00 ADCY3
Coronary Artery Disease (CAD) 2.0 1 0 0.0 0.00 1.0e+00 C6orf106
Crohns Disease (2012) 1.5 1 1 2.2 0.00 1.0e+00 P4HA2
Fasting Glucose 1.4 1 1 2.2 0.00 1.0e+00 NOSTRIN
HDL Cholesterol 1.9 1 1 2.2 0.00 1.0e+00 C6orf106
LDL Cholesterol 2.0 1 1 2.2 0.00 1.0e+00 C6orf106
Lupus 1.6 1 0 0.0 0.00 1.0e+00 ZNF76
Rheumatoid Arthritis 1.5 1 0 0.0 0.00 1.0e+00 CDK6
Schizophrenia (2014) 1.3 2 1 2.2 0.00 1.0e+00 AC103965.1 LIN28B
Triglycerides 1.2 1 0 0.0 0.00 1.0e+00 TP53INP2
Type 2 Diabetes (T2D) (2012) 2.1 1 1 2.2 0.00 1.0e+00 JAZF1
Ulcerative Colitis 2.1 2 1 2.2 0.00 1.0e+00 GNA12 SEC16A
Blood Eosinophil Count 2.3 14 6 13.3 -0.35 2.2e-01 AC103965.1 CDK6 CRLF3 DLEU2 GNA12 JAZF1 NOSTRIN P4HA2 RAB24 RP11-73O6.3 RPL10A SEC16A SEMA3B-AS1 ZNF76
Blood Platelet Count 2.0 17 13 28.9 -0.81 1.8e-05 AC103965.1 BCS1L C6orf106 CDK6 CRLF3 DCAF16 DDX42 DYM E2F1 GNA12 OTUD4 P4HA2 RIOK3 RP11-848P1.7 SCMH1 TMEM180 TSSK6
Blood Red Count 1.8 16 10 22.2 0.01 9.5e-01 AC103965.1 BCS1L C17orf82 C6orf106 CENPW DOT1L E2F1 GPR126 IL23A RAD9A RP11-435O5.5 RP11-73O6.3 SEC16A SEMA3B-AS1 TSSK6 ZBTB38
Blood White Count 2.2 21 13 28.9 -0.40 7.0e-02 BCS1L C6orf106 CASKIN1 CDK6 CENPW DCAF16 DDX42 EBPL GGT7 GNA12 NOSTRIN P4HA2 RIOK3 RP11-435O5.5 RP11-73O6.3 RPL10A SCMH1 SEC16A TMEM180 TRA2A ZNF76
Heel T-Score 3.8 37 28 62.2 -0.67 4.2e-06 ADCY3 ANAPC10 BMP6 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL GGT7 GNA12 GPR126 GSDMC H1FX LIN28B MST1P9 PDE6D RAB24 RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RPL10A SCMH1 UQCC1 ZBTB38 ZNF76
BMI 2.7 19 11 24.4 -0.15 5.0e-01 ADCY3 C17orf82 C6orf106 CASKIN1 CHRNB1 DCAF16 DDX42 DIS3L2 DYM GPR126 GSDMC JAZF1 LOXL1-AS1 MST1P9 OTUD4 RAB24 RIOK3 RP11-73O6.3 TSSK6
Height 30.4 70 70 155.6 0.98 6.5e-52 AC103965.1 ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 KDM5A LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A SEMA3B-AS1 TMEM180 TOP3A TP53INP2 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Waist Hip Ratio (WHR) 4.8 28 21 46.7 -0.24 1.9e-01 AC103965.1 ADCY3 AKR1C3 ANAPC10 C17orf82 C6orf106 CENPW CEP250 CHRNB1 DLEU2 DOT1L DYM EBPL GDF5 H1FX JAZF1 MST1P9 OTUD4 RAB24 RAD9A RIOK3 RP11-529H20.5 RP11-73O6.3 SCN4A TOP3A UQCC UQCC1 ZBTB38
Systolic Blood Pressure 2.0 14 6 13.3 0.13 6.3e-01 ADCY3 BMP6 C17orf82 CDK6 CEP250 DCAF16 EFEMP1 GDF5 GPR126 JAZF1 RPL10A SCMH1 SEMA3B-AS1 UQCC
Smoking Status 1.4 2 0 0.0 0.00 1.0e+00 C6orf106 TMEM180
Allergy or Eczema 2.4 7 3 6.7 -0.03 9.3e-01 C6orf106 CCDC66 GNA12 JAZF1 P4HA2 TMEM180 ZBTB38
Cardiovascular Disease 1.6 7 2 4.4 -0.55 2.0e-01 C17orf82 C6orf106 CDK6 CRLF3 DCAF16 RIOK3 ZNF76
Respiratory disease 1.7 2 2 4.4 0.00 1.0e+00 P4HA2 ZNF76
Type 2 Diabetes (T2D) (2018) 2.0 2 1 2.2 0.00 1.0e+00 CENPW JAZF1
Lung FEV1/FVC ratio 6.3 24 15 33.3 0.00 9.9e-01 AC103965.1 ADCY3 C6orf106 CDKN2C CENPW CEP250 EFEMP1 GDF5 GGT7 GNA12 GPR126 LOXL1-AS1 MMP24 MST1P9 OTUD4 P4HA2 RP11-435O5.5 RPL10A TOP3A TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Lung FVC 6.4 39 30 66.7 -0.41 6.5e-03 ANAPC10 BMP6 C17orf82 C6orf106 CCDC91 CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DOT1L EBPL EFEMP1 GDF5 GSDMC JAZF1 LIN28B LOXL1-AS1 MMP24 MST1P9 P4HA2 PDE6D RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A SEMA3B-AS1 TP53INP2 UQCC UQCC1 ZBTB38 ZNF76
Neuroticism 1.4 4 0 0.0 -0.99 1.0e-02 CENPW LIN28B TMEM180 TP53INP2
Chronotype (morning person) 1.4 2 1 2.2 0.00 1.0e+00 SEC16A SEMA3B-AS1
Hair Pigment 12.2 17 12 26.7 -0.44 5.4e-02 ADCY3 CENPW CEP250 DBNDD1 E2F1 GDF5 GGT7 JAZF1 MMP24 RP11-196G18.22 RP11-73O6.3 SEC16A TP53INP2 UQCC UQCC1 ZBTB38 ZNF76
Tanning 15.0 11 10 22.2 0.69 6.4e-03 ADCY3 CEP250 DBNDD1 E2F1 GDF5 GGT7 JAZF1 MMP24 TP53INP2 UQCC UQCC1
Hand grip strength (left) 8.1 27 17 37.8 0.97 6.7e-18 ADCY3 BCS1L BMP6 CASKIN1 CEP250 CHRNB1 DCAF16 DOT1L DYM GDF5 GGT7 H1FX LIN28B LOXL1-AS1 MMP24 MST1P9 P4HA2 RAD9A RP11-73O6.3 SCN4A TMEM180 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Number of treatments/medications taken 1.6 3 0 0.0 0.00 1.0e+00 C6orf106 DCAF16 LIN28B
Relative age of first facial hair 3.3 7 4 8.9 0.28 4.7e-01 C6orf106 DBNDD1 LIN28B SCMH1 SEMA3B-AS1 UQCC ZBTB38
Systolic blood pressure, automated reading 1.8 6 2 4.4 -0.77 7.2e-02 ADCY3 C17orf82 CDK6 DCAF16 EFEMP1 RPL10A
Medication: Metformin 1.9 1 1 2.2 0.00 1.0e+00 JAZF1
Impedance of leg (right) 4.1 27 14 31.1 -0.20 2.7e-01 AC103965.1 ADCY3 BCS1L C6orf106 CDK6 CEP250 CTD-3076O17.1 E2F1 GDF5 GSDMC H1FX JAZF1 LIN28B MMP24 MST1P9 OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SCMH1 SCN4A SEMA3B-AS1 TOP3A TP53INP2 UQCC UQCC1
Leg fat-free mass (left) 16.4 58 45 100.0 0.95 3.3e-33 AKR1C3 ANAPC10 BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX KDM5A LIN28B LOXL1-AS1 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Trunk fat percentage 3.4 15 10 22.2 0.74 6.2e-04 AC103965.1 ADCY3 C6orf106 CASKIN1 CENPW CTD-3076O17.1 EFEMP1 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-196G18.22 RPL10A ZBTB38
Hand grip strength (right) 9.4 32 19 42.2 0.96 5.7e-20 ADCY3 AKR1C3 BCS1L BMP6 C6orf106 CASKIN1 CEP250 CHRNB1 DCAF16 DDX42 DOT1L DYM E2F1 GDF5 GGT7 H1FX LIN28B LOXL1-AS1 MMP24 MST1P9 P4HA2 RAD9A RP11-73O6.3 SCMH1 SCN4A TMEM180 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Relative age voice broke 3.2 4 1 2.2 -0.55 2.6e-01 GDF5 LIN28B SCMH1 UQCC
Age when periods started (menarche) 3.9 5 3 6.7 0.34 5.8e-01 ADCY3 CENPW LIN28B SCMH1 SEMA3B-AS1
Heel bone mineral density (BMD) T-score, automated (left) 2.0 5 2 4.4 -0.98 2.2e-03 CDK6 DLEU2 EBPL LIN28B RP11-435O5.5
High blood pressure 1.4 4 0 0.0 -0.74 2.6e-01 C17orf82 C6orf106 DCAF16 P4HA2
Hayfever, allergic rhinitis or eczema 2.1 5 2 4.4 -0.21 6.1e-01 C6orf106 CCDC66 P4HA2 TMEM180 ZBTB38
Sitting height 25.5 63 60 133.3 0.93 5.3e-32 AC103965.1 ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LOXL1-AS1 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Body mass index (BMI) 2.5 11 3 6.7 -0.02 9.5e-01 ADCY3 C17orf82 C6orf106 DCAF16 DDX42 DIS3L2 JAZF1 OTUD4 RIOK3 RP11-73O6.3 TSSK6
Impedance of leg (left) 4.0 25 13 28.9 -0.19 3.3e-01 AC103965.1 ADCY3 BCS1L C6orf106 CDK6 CEP250 CTD-3076O17.1 E2F1 GDF5 GPR126 H1FX JAZF1 LIN28B MST1P9 OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SCN4A SEMA3B-AS1 TOP3A TP53INP2 UQCC UQCC1
Leg predicted mass (left) 16.4 57 45 100.0 0.95 4.5e-33 AKR1C3 ANAPC10 BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX KDM5A LIN28B LOXL1-AS1 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Trunk fat mass 6.5 29 23 51.1 0.91 3.6e-14 AC103965.1 ADCY3 ANAPC10 C6orf106 CASKIN1 CDK6 CEP250 CTD-3076O17.1 DBNDD1 E2F1 EFEMP1 GDF5 GGT7 GNA12 GPR126 H1FX LIN28B MFGE8 OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-73O6.3 RP11-848P1.7 RPL10A TSEN15 UQCC UQCC1 ZBTB38
Waist circumference 3.8 15 10 22.2 0.81 5.2e-05 AC103965.1 ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-848P1.7 RPL10A TSSK6 ZBTB38
Past tobacco smoking 1.7 1 0 0.0 0.00 1.0e+00 TMEM180
Alcohol usually taken with meals 1.3 1 0 0.0 0.00 1.0e+00 CHRNB1
Nervous feelings 1.7 2 0 0.0 0.00 1.0e+00 CENPW TP53INP2
Hearing difficulty/problems with background noise 1.2 2 0 0.0 0.00 1.0e+00 LIN28B TMEM180
Hair/balding pattern: Pattern 2 1.7 1 0 0.0 0.00 1.0e+00 CENPW
Had menopause 1.5 1 0 0.0 0.00 1.0e+00 RP11-73O6.3
Forced vital capacity (FVC) 11.9 48 35 77.8 0.93 1.8e-24 AC103965.1 ADCY3 ANAPC10 BCS1L C6orf106 CCDC66 CDK6 CDKN2C CENPW CEP250 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A LOXL1-AS1 MAPK9 MFGE8 MST1P9 NOSTRIN OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RPL10A SCMH1 SCN4A TMEM180 TRA2A TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Heel bone mineral density (BMD) T-score, automated (right) 2.1 5 1 2.2 -0.95 1.1e-02 CDK6 DLEU2 EBPL RP11-435O5.5 ZBTB38
Qualifications: None of the above 1.7 2 0 0.0 0.00 1.0e+00 CENPW UQCC1
Allergy 2.3 8 3 6.7 0.00 9.9e-01 C6orf106 CCDC66 GNA12 JAZF1 P4HA2 SEMA3B-AS1 TMEM180 ZBTB38
Diabetes (self-reported) 2.0 3 1 2.2 0.00 1.0e+00 AKR1C3 JAZF1 SEC16A
Medication: Ramipril 1.4 1 0 0.0 0.00 1.0e+00 C6orf106
Fluid intelligence score 1.5 2 0 0.0 0.00 1.0e+00 DCAF16 RP11-435O5.5
Neuroticism score 1.1 1 0 0.0 0.00 1.0e+00 TP53INP2
Weight 12.0 49 38 84.4 0.95 3.9e-29 AC103965.1 ANAPC10 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DLEU2 DOT1L E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX MFGE8 MMP24 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38
Impedance of arm (right) 3.7 20 13 28.9 0.23 3.1e-01 AC103965.1 C6orf106 CASKIN1 CENPW CEP250 CTD-3076O17.1 E2F1 EFEMP1 GPR126 JAZF1 LIN28B LOXL1-AS1 MFGE8 MST1P9 RP11-196G18.22 RP11-529H20.5 RP11-73O6.3 SCMH1 TP53INP2 TSSK6
Arm fat percentage (right) 2.5 12 6 13.3 -0.16 5.7e-01 ADCY3 C17orf82 C6orf106 CENPW CHRNB1 DCAF16 DDX42 GNA12 RIOK3 RP11-196G18.22 SCN4A ZNF76
Trunk fat-free mass 21.8 62 59 131.1 0.96 1.5e-38 ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Hip circumference 8.4 36 26 57.8 0.92 9.6e-19 AC103965.1 ADCY3 ANAPC10 C6orf106 CASKIN1 CCDC66 CDK6 CDKN2C CEP250 CRLF3 DBNDD1 DLEU2 DOT1L E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 H1FX NOSTRIN OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38
Worrier / anxious feelings 1.2 1 0 0.0 0.00 1.0e+00 TMEM180
Frequency of tiredness / lethargy in last 2 weeks 1.5 1 0 0.0 0.00 1.0e+00 GGT7
Hair/balding pattern: Pattern 3 2.0 1 1 2.2 0.00 1.0e+00 CENPW
Forced expiratory volume in 1-second (FEV1) 9.4 41 27 60.0 0.94 4.0e-22 AC103965.1 ADCY3 ANAPC10 BCS1L C6orf106 CDK6 CDKN2C CENPW CEP250 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DLEU2 E2F1 EBPL EFEMP1 GDF5 GGT7 GSDMC H1FX LOXL1-AS1 MAPK9 MFGE8 MST1P9 NOSTRIN OTUD4 P4HA2 RAB24 RAD9A RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RPL10A SCMH1 SCN4A TMEM180 TRA2A UQCC ZBTB38 ZNF76
Pulse rate 1.4 1 1 2.2 0.00 1.0e+00 ZBTB38
Qualifications: A levels/AS levels or equivalent 1.9 5 0 0.0 0.97 1.5e-03 CHRNB1 DCAF16 GDF5 UQCC UQCC1
Mouth/teeth dental problems: Dentures 1.2 1 0 0.0 0.00 1.0e+00 TP53INP2
Asthma 2.0 2 2 4.4 0.00 1.0e+00 P4HA2 ZNF76
Illnesses of mother 1.3 1 0 0.0 0.00 1.0e+00 DCAF16
Forced expiratory volume in 1-second (FEV1), Best measure 9.3 39 27 60.0 0.94 1.5e-21 AC103965.1 ADCY3 ANAPC10 BCS1L C6orf106 CDK6 CDKN2C CENPW CEP250 CTD-3076O17.1 DCAF16 DDX42 DLEU2 E2F1 EBPL EFEMP1 GDF5 GGT7 GSDMC H1FX IL23A LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 OTUD4 P4HA2 RAB24 RAD9A RP11-73O6.3 RPL10A SCMH1 SCN4A TMEM180 TRA2A UQCC ZBTB38 ZNF76
Impedance of arm (left) 3.8 21 13 28.9 0.38 9.1e-02 AC103965.1 C6orf106 CENPW CTD-3076O17.1 E2F1 EFEMP1 GNA12 GPR126 JAZF1 LIN28B LOXL1-AS1 MFGE8 MST1P9 RAD9A RIOK3 RP11-196G18.22 RP11-529H20.5 RP11-73O6.3 SCMH1 TP53INP2 TSSK6
Arm fat mass (right) 3.8 16 13 28.9 0.82 4.7e-06 ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GDF5 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-73O6.3 RPL10A UQCC ZBTB38
Trunk predicted mass 21.8 63 60 133.3 0.96 1.2e-38 ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Standing height 29.9 70 70 155.6 0.98 1.7e-53 AC103965.1 ADCY3 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 KDM5A LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A SEMA3B-AS1 TMEM180 TOP3A TP53INP2 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Tense / 'highly strung' 1.3 2 0 0.0 0.00 1.0e+00 RP11-196G18.22 TP53INP2
Hair/balding pattern: Pattern 4 2.2 3 2 4.4 0.00 1.0e+00 CDKN2C CENPW ZBTB38
Birth weight of first child 2.8 6 3 6.7 0.94 4.6e-03 ANAPC10 DCAF16 OTUD4 RP11-73O6.3 ZBTB38 ZNF76
Peak expiratory flow (PEF) 6.8 25 14 31.1 0.98 3.8e-20 ADCY3 ANAPC10 C6orf106 CDKN2C CEP250 DCAF16 DLEU2 EBPL EFEMP1 GDF5 GGT7 GSDMC H1FX LOXL1-AS1 MMP24 NOSTRIN OTUD4 RAD9A RP11-73O6.3 RPL10A SCN4A TMEM180 UQCC UQCC1 ZNF76
Pulse wave reflection index 1.5 1 0 0.0 0.00 1.0e+00 TSSK6
Blood clot in the leg (DVT) 1.8 3 0 0.0 0.00 1.0e+00 E2F1 MMP24 TP53INP2
Birth weight 4.1 12 5 11.1 0.85 5.1e-04 ANAPC10 CDK6 CENPW CRLF3 DCAF16 GDF5 GNA12 GPR126 RP11-435O5.5 RP11-73O6.3 TRA2A ZNF76
Chronic bronchitis/emphysema (mother) 2.0 1 0 0.0 0.00 1.0e+00 DBNDD1
Forced vital capacity (FVC), Best measure 11.8 48 36 80.0 0.94 6.1e-25 AC103965.1 ADCY3 ANAPC10 BCS1L C6orf106 CCDC66 CDK6 CDKN2C CENPW CEP250 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DLEU2 DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-435O5.5 RP11-73O6.3 RPL10A SCMH1 SCN4A TMEM180 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Body fat percentage 2.8 14 7 15.6 0.30 2.6e-01 AC103965.1 ADCY3 C6orf106 CASKIN1 CENPW CHRNB1 CTD-3076O17.1 DCAF16 DDX42 GNA12 RIOK3 RP11-196G18.22 ZBTB38 ZNF76
Leg fat percentage (right) 3.1 14 11 24.4 -0.42 9.1e-02 AC103965.1 ADCY3 C6orf106 CENPW CEP250 DCAF16 DDX42 GDF5 MMP24 RIOK3 RP11-435O5.5 SCN4A TSSK6 UQCC
Arm fat-free mass (right) 18.4 57 52 115.6 0.96 5.4e-36 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Comparative body size at age 10 3.5 7 2 4.4 -0.66 1.1e-01 ADCY3 DBNDD1 DIS3L2 DOT1L LIN28B RP11-529H20.5 TP53INP2
Worry too long after embarrassment 1.6 1 0 0.0 0.00 1.0e+00 TP53INP2
Number of children fathered 1.3 1 0 0.0 0.00 1.0e+00 IL23A
Age at first live birth 1.2 1 0 0.0 0.00 1.0e+00 DCAF16
Qualifications: College or University degree 1.5 6 0 0.0 0.75 5.2e-02 CENPW DDX42 GDF5 RIOK3 UQCC UQCC1
Mouth/teeth dental problems: Loose teeth 1.3 1 1 2.2 0.00 1.0e+00 CCDC91
Medication for pain relief, constipation, heartburn 1.8 1 0 0.0 0.00 1.0e+00 C6orf106
Medication: Omeprazole 1.8 1 0 0.0 0.00 1.0e+00 C6orf106
Medication: Seretide 50 evohaler 1.1 1 0 0.0 0.00 1.0e+00 P4HA2
Mean time to correctly identify matches 1.3 2 0 0.0 0.00 1.0e+00 CCDC66 RP11-73O6.3
Whole body fat mass 5.2 24 18 40.0 0.88 1.5e-10 AC103965.1 ADCY3 ANAPC10 C6orf106 CASKIN1 CDK6 CEP250 CTD-3076O17.1 E2F1 EFEMP1 GDF5 GGT7 GNA12 GPR126 H1FX OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-73O6.3 RPL10A UQCC UQCC1 ZBTB38
Leg fat mass (right) 3.7 15 11 24.4 0.78 1.2e-04 AC103965.1 ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-73O6.3 RPL10A TSSK6 ZBTB38
Arm predicted mass (right) 18.3 57 52 115.6 0.96 8.6e-36 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Pulse rate, automated reading 1.5 4 2 4.4 0.41 4.2e-01 C6orf106 CHRNB1 JAZF1 ZBTB38
Alcohol intake frequency. 1.0 2 1 2.2 0.00 1.0e+00 RIOK3 TOP3A
Comparative height size at age 10 25.4 66 63 140.0 0.97 4.3e-44 AC103965.1 ADCY3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 CTD-3076O17.1 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 KDM5A LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TOP3A TP53INP2 TRA2A TSEN15 TSSK6 UQCC UQCC1 ZBTB38 ZNF76
Overall health rating 1.8 2 1 2.2 -0.78 2.2e-01 C6orf106 DCAF16
Family relationship satisfaction 1.1 1 0 0.0 0.00 1.0e+00 RP11-73O6.3
Knee pain experienced in last month 4.0 3 3 6.7 -0.99 5.8e-04 CEP250 GDF5 UQCC
Hypertension (Self-reported) 1.4 4 0 0.0 -0.72 2.8e-01 C17orf82 C6orf106 DCAF16 P4HA2
Illnesses of father: Heart disease 1.5 1 0 0.0 0.00 1.0e+00 GGT7
Whole body fat-free mass 20.0 62 54 120.0 0.95 2.9e-36 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Leg fat-free mass (right) 16.7 59 46 102.2 0.95 6.3e-33 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX KDM5A LIN28B LOXL1-AS1 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Arm fat percentage (left) 2.6 12 7 15.6 -0.14 6.3e-01 ADCY3 C17orf82 C6orf106 CENPW CHRNB1 DCAF16 DDX42 GNA12 RIOK3 RP11-196G18.22 SCN4A ZNF76
Average weekly red wine intake 1.6 1 0 0.0 0.00 1.0e+00 RIOK3
Diabetes diagnosed by doctor 2.1 2 1 2.2 0.00 1.0e+00 CENPW JAZF1
Medication for cholesterol 1.9 1 0 0.0 0.00 1.0e+00 C6orf106
Back pain experienced in last month 1.8 1 0 0.0 0.00 1.0e+00 C6orf106
Breast cancer (self-reported) 1.4 1 0 0.0 0.00 1.0e+00 CDKN2C
Asthma (self-reported) 1.9 3 2 4.4 0.00 1.0e+00 P4HA2 ZBTB38 ZNF76
Medication: Gliclazide 1.5 1 0 0.0 0.00 1.0e+00 JAZF1
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.9 8 2 4.4 -0.51 2.0e-01 BMP6 CCDC91 GDF5 GPR126 JAZF1 RPL10A UQCC ZNF76
Whole body water mass 19.6 61 54 120.0 0.95 5.3e-36 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Leg predicted mass (right) 16.6 58 46 102.2 0.95 4.9e-33 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX KDM5A LIN28B LOXL1-AS1 MFGE8 MMP24 NOSTRIN OTUD4 P4HA2 PDE6D RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Arm fat mass (left) 3.9 16 13 28.9 0.82 5.1e-06 ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GDF5 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-196G18.22 RP11-73O6.3 RPL10A UQCC ZBTB38
Number of self-reported non-cancer illnesses 1.5 1 0 0.0 0.00 1.0e+00 P4HA2
Miserableness 1.1 1 0 0.0 0.00 1.0e+00 LOXL1-AS1
Guilty feelings 1.4 1 1 2.2 0.00 1.0e+00 LIN28B
Commuting to job workplace: Public transport 1.0 1 0 0.0 0.00 1.0e+00 SEMA3B-AS1
Medication: Blood pressure 1.7 2 2 4.4 0.00 1.0e+00 C6orf106 P4HA2
High cholesterol (Self-reported) 1.6 1 0 0.0 0.00 1.0e+00 DCAF16
Medication: Bendroflumethiazide 1.3 1 0 0.0 0.00 1.0e+00 P4HA2
Ever smoked 1.1 1 0 0.0 0.00 1.0e+00 TMEM180
Basal metabolic rate 18.4 63 51 113.3 0.95 6.9e-36 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DBNDD1 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX IL23A JAZF1 LIN28B LOXL1-AS1 MAPK9 MFGE8 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-196G18.22 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Leg fat percentage (left) 3.1 15 10 22.2 -0.44 6.8e-02 AC103965.1 ADCY3 C6orf106 CENPW CEP250 DCAF16 DDX42 GDF5 MMP24 RIOK3 RP11-435O5.5 SCN4A TSSK6 UQCC ZNF76
Arm fat-free mass (left) 17.9 57 51 113.3 0.96 3.4e-35 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Number of operations (self-reported) 1.9 2 0 0.0 0.00 1.0e+00 GNA12 LIN28B
Irritability 1.4 2 1 2.2 0.00 1.0e+00 RP11-73O6.3 TP53INP2
Ever had prostate specific antigen (PSA) test 1.5 1 0 0.0 0.00 1.0e+00 ZBTB38
Diastolic blood pressure, automated reading 1.5 6 1 2.2 -0.81 4.8e-02 ADCY3 C17orf82 DCAF16 P4HA2 SCMH1 ZNF76
Myopia 1.9 1 0 0.0 0.00 1.0e+00 C6orf106
Vascular/heart problems diagnosed by doctor 1.6 4 2 4.4 0.73 2.7e-01 C17orf82 C6orf106 DCAF16 P4HA2
Cholesterol lowering medication 1.6 1 0 0.0 0.00 1.0e+00 DDX42
Pain experienced in last month 1.6 1 0 0.0 0.00 1.0e+00 CENPW
Basal cell carcinoma (self-reported) 1.8 2 0 0.0 0.00 1.0e+00 DBNDD1 TP53INP2
Deep venous thrombosis (DVT) (self-reported) 1.8 4 0 0.0 0.66 3.4e-01 CHRNB1 E2F1 MMP24 TP53INP2
Impedance of whole body 3.9 25 20 44.4 -0.03 8.8e-01 AC103965.1 ADCY3 C6orf106 CENPW CEP250 CTD-3076O17.1 E2F1 EFEMP1 GDF5 GPR126 JAZF1 LIN28B MST1P9 OTUD4 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SCMH1 SCN4A SEMA3B-AS1 TOP3A TP53INP2 TSSK6 UQCC
Leg fat mass (left) 3.8 15 10 22.2 0.78 1.2e-04 AC103965.1 ADCY3 C6orf106 CASKIN1 CDK6 E2F1 GGT7 GNA12 OTUD4 RAD9A RIOK3 RP11-73O6.3 RPL10A TSSK6 ZBTB38
Arm predicted mass (left) 17.8 57 51 113.3 0.96 6.5e-35 AKR1C3 ANAPC10 BCS1L BMP6 C17orf82 C6orf106 CASKIN1 CCDC66 CCDC91 CDK6 CDKN2C CENPW CEP250 CHRNB1 CRLF3 DCAF16 DDX42 DIS3L2 DLEU2 DOT1L DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC H1FX JAZF1 LOXL1-AS1 MAPK9 MMP24 MST1P9 NOSTRIN OTUD4 P4HA2 PDE6D RAB24 RAD9A RIOK3 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A SCMH1 SCN4A SEC16A TMEM180 TP53INP2 TRA2A TSEN15 UQCC UQCC1 ZBTB38 ZNF76

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 22 0.63 2.3
GTEx Adipose Visceral Omentum 9 0.44 2.2
GTEx Adrenal Gland 6 0.41 2.1
GTEx Artery Aorta 16 0.54 2.2
GTEx Artery Coronary 4 0.34 2.1
GTEx Artery Tibial 27 0.72 2.3
GTEx Brain Caudate basal ganglia 2 0.22 2.0
GTEx Brain Cerebellar Hemisphere 6 0.40 2.1
GTEx Brain Cerebellum 10 0.50 2.2
GTEx Brain Cortex 6 0.58 2.3
GTEx Brain Frontal Cortex BA9 4 0.43 2.1
GTEx Brain Hippocampus 2 0.38 2.3
GTEx Brain Hypothalamus 5 0.85 2.2
GTEx Brain Nucleus accumbens basal ganglia 5 0.58 2.2
GTEx Brain Putamen basal ganglia 4 0.64 2.1
GTEx Breast Mammary Tissue 11 0.56 2.1
GTEx Breast Mammary Tissue (Male) 10 0.84 2.3
GTEx Breast Mammary Tissue (Female) 7 0.43 2.1
GTEx Cells EBV-transformed lymphocytes 10 0.70 2.2
GTEx Cells Transformed fibroblasts 15 0.36 2.1
GTEx Colon Sigmoid 5 0.34 2.2
GTEx Colon Transverse 13 0.63 2.2
GTEx Esophagus Gastroesophageal Junction 7 0.48 2.1
GTEx Esophagus Mucosa 26 0.78 2.2
GTEx Esophagus Muscularis 17 0.53 2.2
GTEx Heart Atrial Appendage 11 0.70 2.2
GTEx Heart Left Ventricle 4 0.26 2.0
GTEx Liver 3 0.42 2.1
GTEx Lung 17 0.59 2.2
GTEx Muscle Skeletal 17 0.59 2.2
GTEx Nerve Tibial 28 0.65 2.2
GTEx Ovary 4 0.44 2.3
GTEx Pancreas 11 0.67 2.2
GTEx Pituitary 10 0.90 2.3
GTEx Prostate 2 0.24 2.1
GTEx Skin Not Sun Exposed Suprapubic 15 0.61 2.1
GTEx Skin Sun Exposed Lower leg 21 0.58 2.2
GTEx Small Intestine Terminal Ileum 2 0.43 2.1
GTEx Spleen 7 0.50 2.2
GTEx Stomach 11 0.76 2.1
GTEx Testis 21 0.67 2.3
GTEx Thyroid 23 0.58 2.2
GTEx Uterus 0 0.00 2.0
GTEx Vagina 1 0.16 1.8
GTEx Whole Blood 9 0.45 2.2
METSIM Adipose 17 0.37 2.0
NTR Blood 10 0.42 2.0
ROSMAP Brain Pre-frontal Cortex 18 0.41 2.1
YFS Blood 17 0.37 1.9
CommonMind Brain Pre-frontal Cortex 23 0.43 2.0
The Cancer Genome Atlas Bladder Urothelial Carcinoma 7 0.42 2.0
The Cancer Genome Atlas Breast Invasive Carcinoma 17 0.39 2.0
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 3 0.27 1.9
The Cancer Genome Atlas Colon Adenocarcinoma 8 0.39 2.1
The Cancer Genome Atlas Esophageal Carcinoma 4 0.58 1.9
The Cancer Genome Atlas Glioblastoma Multiforme 3 0.29 2.0
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 12 0.44 2.1
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 15 0.37 2.0
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 6 0.29 2.0
The Cancer Genome Atlas Brain Lower Grade Glioma 20 0.46 2.1
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 6 0.54 2.0
The Cancer Genome Atlas Lung Adenocarcinoma 13 0.44 1.9
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 10 0.40 1.9
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 4 0.25 2.0
The Cancer Genome Atlas Pancreatic Adenocarcinoma 3 0.18 1.8
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 4 0.30 1.9
The Cancer Genome Atlas Prostate Adenocarcinoma 21 0.45 2.0
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.00 1.9
The Cancer Genome Atlas Soft Tissue Sarcoma 5 0.47 2.1
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.19 1.9
The Cancer Genome Atlas Stomach Adenocarcinoma 2 0.12 2.0
The Cancer Genome Atlas Testicular Germ Cell Tumors 3 0.23 1.8
The Cancer Genome Atlas Thyroid Carcinoma 21 0.41 1.9
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 4 0.79 2.1